254 related articles for article (PubMed ID: 20860051)
1. Revisiting an old friend: manganese-based MRI contrast agents.
Pan D; Caruthers SD; Senpan A; Schmieder AH; Wickline SA; Lanza GM
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2011; 3(2):162-73. PubMed ID: 20860051
[TBL] [Abstract][Full Text] [Related]
2. Manganese-based MRI contrast agents: past, present and future.
Pan D; Schmieder AH; Wickline SA; Lanza GM
Tetrahedron; 2011 Nov; 67(44):8431-8444. PubMed ID: 22043109
[TBL] [Abstract][Full Text] [Related]
3. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?
Neuwelt EA; Hamilton BE; Varallyay CG; Rooney WR; Edelman RD; Jacobs PM; Watnick SG
Kidney Int; 2009 Mar; 75(5):465-74. PubMed ID: 18843256
[TBL] [Abstract][Full Text] [Related]
4. Paramagnetic and Superparamagnetic Inorganic Nanoparticles for T1-Weighted Magnetic Resonance Imaging.
Zeng L; Wu D; Zou R; Chen T; Zhang J; Wu A
Curr Med Chem; 2018; 25(25):2970-2986. PubMed ID: 28292235
[TBL] [Abstract][Full Text] [Related]
5. Current advancement in the development of manganese complexes as magnetic resonance imaging probes.
Daksh S; Kaul A; Deep S; Datta A
J Inorg Biochem; 2022 Dec; 237():112018. PubMed ID: 36244313
[TBL] [Abstract][Full Text] [Related]
6. Paramagnetic inorganic nanoparticles as T1 MRI contrast agents.
Lee SH; Kim BH; Na HB; Hyeon T
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2014; 6(2):196-209. PubMed ID: 24123961
[TBL] [Abstract][Full Text] [Related]
7. Development of manganese-based nanoparticles as contrast probes for magnetic resonance imaging.
Zhen Z; Xie J
Theranostics; 2012; 2(1):45-54. PubMed ID: 22272218
[TBL] [Abstract][Full Text] [Related]
8. One-pot preparation of hydrophilic manganese oxide nanoparticles as T
Li J; Wu C; Hou P; Zhang M; Xu K
Biosens Bioelectron; 2018 Apr; 102():1-8. PubMed ID: 29101783
[TBL] [Abstract][Full Text] [Related]
9. Exceedingly small iron oxide nanoparticles as positive MRI contrast agents.
Wei H; Bruns OT; Kaul MG; Hansen EC; Barch M; Wiśniowska A; Chen O; Chen Y; Li N; Okada S; Cordero JM; Heine M; Farrar CT; Montana DM; Adam G; Ittrich H; Jasanoff A; Nielsen P; Bawendi MG
Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2325-2330. PubMed ID: 28193901
[TBL] [Abstract][Full Text] [Related]
10. The Transition from Metal-Based to Metal-Free Contrast Agents for
Akakuru OU; Iqbal MZ; Saeed M; Liu C; Paunesku T; Woloschak G; Hosmane NS; Wu A
Bioconjug Chem; 2019 Sep; 30(9):2264-2286. PubMed ID: 31380621
[TBL] [Abstract][Full Text] [Related]
11. Synergy between surface and core entrapped metals in a mixed manganese-gadolinium nanocolloid affords safer MR imaging of sparse biomarkers.
Wang K; Pan D; Schmieder AH; Senpan A; Hourcade DE; Pham CT; Mitchell LM; Caruthers SD; Cui G; Wickline SA; Shen B; Lanza GM
Nanomedicine; 2015 Apr; 11(3):601-9. PubMed ID: 25652900
[TBL] [Abstract][Full Text] [Related]
12. Contrast agents: magnetic resonance.
Burtea C; Laurent S; Vander Elst L; Muller RN
Handb Exp Pharmacol; 2008; (185 Pt 1):135-65. PubMed ID: 18626802
[TBL] [Abstract][Full Text] [Related]
13. A new manganese-based oral contrast agent (CMC-001) for liver MRI: pharmacological and pharmaceutical aspects.
Jørgensen JT; Rief M; Brismar TB; Wagner M; Albiin N
Acta Radiol; 2012 Sep; 53(7):707-13. PubMed ID: 22821959
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of magnetic resonance imaging agents: small molecule and nanoparticle.
Chang Y; Lee GH; Kim TJ; Chae KS
Curr Top Med Chem; 2013; 13(4):434-45. PubMed ID: 23432006
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents.
Estelrich J; Sánchez-Martín MJ; Busquets MA
Int J Nanomedicine; 2015; 10():1727-41. PubMed ID: 25834422
[TBL] [Abstract][Full Text] [Related]
16. Characterization of viable and nonviable myocardium at MR imaging: comparison of gadolinium-based extracellular and blood pool contrast materials versus manganese-based contrast materials in a rat myocardial infarction model.
Flacke S; Allen JS; Chia JM; Wible JH; Periasamy MP; Adams MD; Adzamli IK; Lorenz CH
Radiology; 2003 Mar; 226(3):731-8. PubMed ID: 12601183
[TBL] [Abstract][Full Text] [Related]
17. Dendrimer-based nanosized MRI contrast agents.
Kobayashi H; Brechbiel MW
Curr Pharm Biotechnol; 2004 Dec; 5(6):539-49. PubMed ID: 15579043
[TBL] [Abstract][Full Text] [Related]
18. Integration of gadolinium in nanostructure for contrast enhanced-magnetic resonance imaging.
Marasini R; Thanh Nguyen TD; Aryal S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jan; 12(1):e1580. PubMed ID: 31486295
[TBL] [Abstract][Full Text] [Related]
19. The effect of metal ions on endogenous melanin nanoparticles used as magnetic resonance imaging contrast agents.
Chen A; Sun J; Liu S; Li L; Peng X; Ma L; Zhang R
Biomater Sci; 2020 Jan; 8(1):379-390. PubMed ID: 31728481
[TBL] [Abstract][Full Text] [Related]
20. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis.
Bhave G; Lewis JB; Chang SS
J Urol; 2008 Sep; 180(3):830-5; discussion 835. PubMed ID: 18635232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
